Better Chemotherapeutic Response of Small Cell Lung Cancer in Never Smokers than in Smokers
- Author:
Ha-Young PARK
1
;
Hyung-Joo OH
;
Hwa Kyung PARK
;
Joon-Young YOON
;
Chang-Seok YOON
;
Bo Gun KHO
;
Tae-Ok KIM
;
Hong-Joon SHIN
;
Chul-Kyu PARK
;
Yong-Soo KWON
;
Yu-Il KIM
;
Sung-Chul LIM
;
Young-Chul KIM
;
In-Jae OH
Author Information
- Publication Type:Original Article
- From:Tuberculosis and Respiratory Diseases 2025;88(2):334-341
- CountryRepublic of Korea
- Language:English
-
Abstract:
Background:Small cell lung cancer (SCLC) is called ‘smoker’s disease’ because it is strongly associated with smoking and most cases occur in smokers. However, it can also occur in never smokers. We investigated the clinical features of never smokers with SCLC and compared their treatment outcomes with those of smokers with SCLC.
Methods:We retrospectively reviewed the clinical data of patients who had proven SCLC and had received chemotherapy at a single cancer center between July 2002 and April 2021.
Results:Of 1,643 patients, 1,416 (86.2%) were enrolled in this study. A total of 162 (11.4%) and 1,254 (88.6%) patients were never smokers and smokers, respectively. There were more female never smokers than smokers (n=130; 80.2% vs. 79, 6.3%, p=0.000), and the incidence of ischemic heart disease was lower among never smokers than among smokers (4/1,416, [2.5%] vs. 83/1,416 [6.6%], p=0.036). Never smokers showed less symptoms at diagnosis than smokers (80.9% vs. 87.2%, p=0.037); however, they showed more toxicity after first-line treatment (61.7% vs. 47.8%, p=0.001). The objective response rate (ORR) was significantly higher in never smokers (74.1% vs. 59.6%, p=0.000). In the multivariate analysis, never smoking and second-line treatment were associated with a better ORR. However, progression-free survival and overall survival were not significantly different between never smokers and smokers.
Conclusion:In conclusion, never smokers accounted for 11.4% of patients with SCLC. They had distinguishing clinical characteristics and showed better chemotherapeutic responses than smokers.
